It is expected that, by targeting the specific molecules that contributed to the TRAIL-resistant characteristics in these cells [186] and choosing a xenograft models with the most effective MSC-TRAIL integration, such as a pulmonary disease [187] or a metastatic model [188], a better treatment efficacy and tumour homing of MSC-TRAIL can be achieved. Here, TNFSF10 is linked to lung disorder.